Navigation Links
Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union

HAMBURG, Germany, December 16 /PRNewswire/ -- Eppendorf has initiated an import ban for Nanosphere, Inc.'s Verigene(R) and Verigene(R) SP systems for infringement of European patent EP 1 179 180 B2, titled "Method for the identification and/or the quantification of a target compound". The import ban covers any and all imports of the respective products into any country of the European Union. Customs authorities are required to confiscate any violating products.

The patent covers Eppendorf's Silverquant(R) microarray technology, offered in Eppendorf's Silverquant scanner and Silverquant detection kit used e.g. for Eppendorf's own microarrays. The technology is also licensed to two companies for commercialization with their microarrays.

In addition, Eppendorf has successfully initiated an import ban for the Verigene(R) kits based on the German utility model DE 20023342U1, also covering Eppendorf's Silverquant products. This ban prohibits imports into Germany either from outside the EU or from within the EU.

"Considering Nanosphere's announcement of having received the CE mark for the Verigene(R) system, Eppendorf has taken these steps to prevent the introduction of these products that are not licensed to use our patented technology into the European Union", commented Sven Bulow, Managing Director of Eppendorf Biochip Systems GmbH.

Eppendorf AG was founded in Hamburg in 1945 and has more than 2,450 employees worldwide. The company has subsidiaries in 20 countries and is represented in all other markets by distributors.

In fiscal 2008, the company's sales revenues amounted to EUR 410 million with earnings before interest and taxes (EBIT) of EUR 71.9 million.

    Dr. Sven Buelow
    Managing Director
    Eppendorf Biochip Systems GmbH
    Tel: +49-40-538-01-500
    Fax: +49-40-538-01-140

SOURCE Eppendorf AG

SOURCE Eppendorf AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Brunswick Scientific Completes Merger Transaction with Eppendorf
2. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
3. Life on Mars pregnancy test successfully launched
4. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
5. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
6. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. TopoTarget Successfully Buys Back Full Control of Belinostat
9. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
10. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
11. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Post Your Comments:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):